<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625689</url>
  </required_header>
  <id_info>
    <org_study_id>LAIV-BD-01</org_study_id>
    <nct_id>NCT01625689</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine</brief_title>
  <official_title>Assessment of the Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine Among Children Aged 24 Through 59 Months in Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH Vaccine Solutions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase II randomized controlled clinical trial, generally healthy male and female
      children from 24 through 59 months of age will be enrolled in Kamalapur (Dhaka), Bangladesh.
      The study is expected to continue for at least 6 months following vaccination. The
      experimental intervention is Serum Institute of India Ltd's Trivalent, Seasonal Live
      Attenuated Influenza Vaccine (SIIL LAIV). The study vaccine has been formulated according to
      WHO recommendations for the 2011-2012 Northern Hemisphere influenza season. The SIIL LAIV is
      administered in a 0.5 ml intranasal dose (one spray of 0.25 ml per nostril) via a reusable
      sprayer device and a single-use nozzle that produces a fine mist that is primarily deposited
      in the nose and nasopharynx. The comparator vaccine will be an inactive placebo identical in
      appearance to the active vaccine.

      The primary study hypothesis is that LAIV is safe and well tolerated by children aged 24
      through 59 months in Bangladesh. A secondary hypothesis is that LAIV is immunogenic among
      children receiving study vaccine as compared to children receiving placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), All-cause Hospitalizations, and Protocol-defined Wheezing Illness (PDWI) Episodes</measure>
    <time_frame>6 months following vaccination</time_frame>
    <description>PDWI: Participants meeting illness criteria, seeking care in health facility, and with wheeze identified by a study physician
Illness criteria: The presence of one Category A (Fever (&gt;=38°C), tachypnea, danger signs (chest-indrawing, lethargy, cyanosis, inability to drink, convulsions), difficult breathing, noisy breathing, ear pain or discharge) or two Category B findings (Cough, rhinorrhea, sore throat, myalgia/arthralgia, chills, headache, irritability/decreased activity, vomiting)
Wheeze: Long high-pitched whistling or musical sound on expiration heard by auscultation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), All-cause Hospitalizations, and Protocol-defined Wheezing Illness (PDWI) Episodes</measure>
    <time_frame>42 days following vaccination</time_frame>
    <description>PDWI: Participants meeting illness criteria, seeking care in health facility, and with wheeze identified by a study physician
Illness criteria: The presence of one Category A (Fever (&gt;=38°C), tachypnea, danger signs (chest-indrawing, lethargy, cyanosis, inability to drink, convulsions), difficult breathing, noisy breathing, ear pain or discharge) or two Category B findings (Cough, rhinorrhea, sore throat, myalgia/arthralgia, chills, headache, irritability/decreased activity, vomiting)
Wheeze: Long high-pitched whistling or musical sound on expiration heard by auscultation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Throughout study period, through at least 6 months following vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local and Systemic Reactions</measure>
    <time_frame>Through 7 days following vaccination</time_frame>
    <description>Local reactions: Nasal discomfort, Runny nose, Stuffy nose, Sneezing, Ear pain
Systemic Reactions: Cough, Headache, Loss of Appetite, Fever, Irritability, Nausea, Sore throat, Lethargy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Post-vaccination Anti-influenza Immunologic Response Will be Measured Based on the Type of Immunologic Assay and Categorized by Vaccine Virus Strain, Participant Baseline Serostatus, and Vaccine Allocation</measure>
    <time_frame>Approximately 21 days post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Vaccination SIIL LAIV Virus Shedding/Vaccine-take Will be Parameterized by the Percentage of Participants With Detectable Virus by Post Vaccination Day.</measure>
    <time_frame>2, 4, and 7 days post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Characteristics of Influenza, Including Influenza Coinfections With Other Bacterial and Viral Respiratory Pathogens, Will be Parameterized as the Percentage of Participants Categorized by Vaccine Allocation</measure>
    <time_frame>6 months post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Etiologies of Acute Respiratory and Febrile Illness Will be Parameterized as the Percentage of Those With Each Particular Laboratory-confirmed Respiratory Virus Infection Categorized by Vaccine Allocation</measure>
    <time_frame>6 months post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>SIIL LAIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo identical in appearance to experimental vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SIIL LAIV (live, trivalent seasonal influenza vaccine)</intervention_name>
    <description>Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
    <arm_group_label>SIIL LAIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female child at least 24 months of age and no older than 59 months of
             age at the time of study vaccination

          -  A child whose parent or guardian's primary residence, at the time of study
             vaccinations, is within the Kamalapur surveillance site catchment area and who intends
             to be present in the area for the duration of the trial

          -  A child whose parent or legal guardian is willing to provide written informed consent
             prior to the participant's study vaccination

        Exclusion Criteria:

          -  Has any serious chronic disease including progressive neurologic disease,
             tuberculosis, Down's syndrome or other cytogenetic disorder, or known or suspected
             disease of the immune system

          -  Is receiving immunosuppressive agents including systemic corticosteroids during the
             two weeks prior to study vaccination

          -  Has a history of documented hypersensitivity to eggs or other components of the
             vaccine (including gelatin, sorbitol, lactalbumin and chicken protein), or with
             life-threatening reactions to previous influenza vaccinations

          -  Is receiving aspirin therapy or aspirin-containing therapy currently or two weeks
             before

          -  Lives in household with somebody currently participating in a respiratory vaccination
             or antiviral study

          -  Has current or past participation (within 2 months of trial enrollment visit) in any
             clinical trial involving a drug or biologic with activity against respiratory disease

          -  Has any condition determined by investigator as likely to interfere with evaluation of
             the vaccine or be a significant potential health risk to the child
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Abdullah Brooks, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>JHSPH, ICDDR,B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICDDR,B Kamalapur</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>May 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2015</results_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccines</keyword>
  <keyword>Influenza, Human</keyword>
  <keyword>Live Attenuated Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>309 participants were consented and enrolled in the study. 9 participants were ineligible to receive study vaccination. 300 total participants were vaccinated and followed through the study period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Serum Institute of India, Ltd. (SIIL) LAIV</title>
          <description>The Serum Institute of India, Ltd. (SIIL) live attenuated influenza vaccine (LAIV) (human, live attenuated, trivalent seasonal influenza vaccine): The viral strains in are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Inactive placebo was identical to SIIL LAIV in appearance, ingredients, and concentrations, except it was missing attenuated influenza virus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Migration</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled who received a single dose of LAIV or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>SIIL LAIV</title>
          <description>The SIIL LAIV (human, live attenuated, trivalent seasonal influenza vaccine): The viral strains in are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Inactive placebo was identical to the SIIL LAIV in appearance, ingredients, and concentrations, except it was missing attenuated influenza virus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bangladesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs), All-cause Hospitalizations, and Protocol-defined Wheezing Illness (PDWI) Episodes</title>
        <description>PDWI: Participants meeting illness criteria, seeking care in health facility, and with wheeze identified by a study physician
Illness criteria: The presence of one Category A (Fever (&gt;=38°C), tachypnea, danger signs (chest-indrawing, lethargy, cyanosis, inability to drink, convulsions), difficult breathing, noisy breathing, ear pain or discharge) or two Category B findings (Cough, rhinorrhea, sore throat, myalgia/arthralgia, chills, headache, irritability/decreased activity, vomiting)
Wheeze: Long high-pitched whistling or musical sound on expiration heard by auscultation</description>
        <time_frame>6 months following vaccination</time_frame>
        <population>Safety analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>SIIL LAIV</title>
            <description>The SIIL LAIV (human, live attenuated, trivalent seasonal influenza vaccine): The viral strains in are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive placebo was identical to SII LAIV in appearance, ingredients, and concentrations, except it was missing attenuated influenza virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs), All-cause Hospitalizations, and Protocol-defined Wheezing Illness (PDWI) Episodes</title>
          <description>PDWI: Participants meeting illness criteria, seeking care in health facility, and with wheeze identified by a study physician
Illness criteria: The presence of one Category A (Fever (&gt;=38°C), tachypnea, danger signs (chest-indrawing, lethargy, cyanosis, inability to drink, convulsions), difficult breathing, noisy breathing, ear pain or discharge) or two Category B findings (Cough, rhinorrhea, sore throat, myalgia/arthralgia, chills, headache, irritability/decreased activity, vomiting)
Wheeze: Long high-pitched whistling or musical sound on expiration heard by auscultation</description>
          <population>Safety analysis population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protocol Defined Wheezing Illness (PDWI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs), All-cause Hospitalizations, and Protocol-defined Wheezing Illness (PDWI) Episodes</title>
        <description>PDWI: Participants meeting illness criteria, seeking care in health facility, and with wheeze identified by a study physician
Illness criteria: The presence of one Category A (Fever (&gt;=38°C), tachypnea, danger signs (chest-indrawing, lethargy, cyanosis, inability to drink, convulsions), difficult breathing, noisy breathing, ear pain or discharge) or two Category B findings (Cough, rhinorrhea, sore throat, myalgia/arthralgia, chills, headache, irritability/decreased activity, vomiting)
Wheeze: Long high-pitched whistling or musical sound on expiration heard by auscultation</description>
        <time_frame>42 days following vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Unsolicited Adverse Events (AEs)</title>
        <time_frame>Throughout study period, through at least 6 months following vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SIIL LAIV</title>
            <description>The SIIL LAIV (human, live attenuated, trivalent seasonal influenza vaccine): The viral strains in are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive placebo was identical to SII LAIV in appearance, ingredients, and concentrations, except it was missing attenuated influenza virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unsolicited Adverse Events (AEs)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrheal Illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral thrush</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Boil/abscess/skin infection/ulcer/cyst</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helminthiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scabies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain/distension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungal Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local and Systemic Reactions</title>
        <description>Local reactions: Nasal discomfort, Runny nose, Stuffy nose, Sneezing, Ear pain
Systemic Reactions: Cough, Headache, Loss of Appetite, Fever, Irritability, Nausea, Sore throat, Lethargy</description>
        <time_frame>Through 7 days following vaccination</time_frame>
        <population>Safety analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>SIIL LAIV</title>
            <description>The SIIL LAIV (human, live attenuated, trivalent seasonal influenza vaccine): The viral strains in are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive placebo was identical to SII LAIV in appearance, ingredients, and concentrations, except it was missing attenuated influenza virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local and Systemic Reactions</title>
          <description>Local reactions: Nasal discomfort, Runny nose, Stuffy nose, Sneezing, Ear pain
Systemic Reactions: Cough, Headache, Loss of Appetite, Fever, Irritability, Nausea, Sore throat, Lethargy</description>
          <population>Safety analysis population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measured fever (&gt;=38.0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose/nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/decreased activitity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lethargy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;=0.498</p_value>
            <p_value_desc>No comparison between the LAIV and placebo groups by type of solicited reaction had a p-value below 0.498.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Post-vaccination Anti-influenza Immunologic Response Will be Measured Based on the Type of Immunologic Assay and Categorized by Vaccine Virus Strain, Participant Baseline Serostatus, and Vaccine Allocation</title>
        <time_frame>Approximately 21 days post-vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Vaccination SIIL LAIV Virus Shedding/Vaccine-take Will be Parameterized by the Percentage of Participants With Detectable Virus by Post Vaccination Day.</title>
        <time_frame>2, 4, and 7 days post-vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Characteristics of Influenza, Including Influenza Coinfections With Other Bacterial and Viral Respiratory Pathogens, Will be Parameterized as the Percentage of Participants Categorized by Vaccine Allocation</title>
        <time_frame>6 months post-vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Etiologies of Acute Respiratory and Febrile Illness Will be Parameterized as the Percentage of Those With Each Particular Laboratory-confirmed Respiratory Virus Infection Categorized by Vaccine Allocation</title>
        <time_frame>6 months post-vaccination</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout study period, through at least 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SIIL LAIV</title>
          <description>The SIIL LAIV (human, live attenuated, trivalent seasonal influenza vaccine): The viral strains in are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Inactive placebo was identical to SII LAIV in appearance, ingredients, and concentrations, except it was missing attenuated influenza virus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain/gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic Injury/fracture/overdose</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrheal illness</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Abdominal pain/distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral thrush</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Boil/Abscess/skin infection/ulcer/cyst</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Helminthiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Scabies</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Clinical Research Scientist</name_or_title>
      <organization>PATH</organization>
      <phone>206-285-3500</phone>
      <email>klewis@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

